RU2006115916A - Комбинированная терапия hcv инфекции - Google Patents
Комбинированная терапия hcv инфекции Download PDFInfo
- Publication number
- RU2006115916A RU2006115916A RU2006115916/15A RU2006115916A RU2006115916A RU 2006115916 A RU2006115916 A RU 2006115916A RU 2006115916/15 A RU2006115916/15 A RU 2006115916/15A RU 2006115916 A RU2006115916 A RU 2006115916A RU 2006115916 A RU2006115916 A RU 2006115916A
- Authority
- RU
- Russia
- Prior art keywords
- interferon
- therapeutic combination
- day
- patient
- combination according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (19)
2. Терапевтическая комбинация по п.1, включающая VX-497 в количестве от 100 мг/день до 110 мг/день.
3. Терапевтическая комбинация по п.2, включающая VX-497 в количестве 100 мг/день.
4. Терапевтическая комбинация по п.1, включающая рибавирин в количестве от 800 мг/день до 1200 мг/день.
5. Терапевтическая комбинация по п.4, включающая рибавирин в количестве от 1000 мг/день до 1200 мг/день.
6. Терапевтическая комбинация по п.5, включающая рибавирин в количестве 1000 мг/день или 1200 мг/день.
7. Терапевтическая комбинация по п.1, в которой указанный интерферон является интерфероном альфа 2а.
8. Терапевтическая комбинация по п.1, в которой указанный интерферон выбран из: интерферона альфа-2b, пегиинтерферона альфа-2b, пегиинтерферона альфа-2а, рекомбинантного интерферона альфа-2а, интерферона альфа 2, очищенной смеси природных альфа-интерферонов, интерферона альфа-n1, консенсусного альфа интерферона или природных альфа интерферонов.
9. Терапевтическая комбинация по п.1, включающая указанный интерферон в количестве от 8 миллионов ME до 9 миллионов ME.
10. Терапевтическая комбинация по п.9, включающая указанный интерферон в количестве 9 миллионов ME.
11. Терапевтическая комбинация по п.1, включающая указанный интерферон в количестве, достаточном для дозировки 1,5 мкг/кг/неделя.
12. Набор, включающий
(I) терапевтическую комбинацию по любому из пп.1-9; и
(II) инструкции по использованию указанной комбинации.
13. Способ лечения HCV инфекции или облегчения одного или более ее симптомов у пациента, включающий стадию введения пациенту терапевтической комбинации по п.1.
14. Способ по п.13, где HCV инфекция является генотипом 1.
15. Способ по п.14, где указанный пациент является неподвергавшимся лечению пациентом.
16. Способ по п.14, в котором указанный пациент является нечувствительным к монотерапии интерфероном.
17. Способ по п.14, в котором указанный пациент является пациентом, нечувствительным к комбинированной терапии, в которой используют рибавирин и интерферон.
18. Способ уменьшения уровней HCV-PHK у пациента, нуждающегося в этом, включающий стадию введения указанному пациенту терапевтической комбинации по п.1.
19. Способ по п.18, где указанные уровни HCV-PHK у пациента снижены до уровня, меньшего, чем обнаруживаемый уровень.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51073303P | 2003-10-11 | 2003-10-11 | |
US60/510,733 | 2003-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2006115916A true RU2006115916A (ru) | 2007-12-10 |
Family
ID=34465143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006115916/15A RU2006115916A (ru) | 2003-10-11 | 2004-10-12 | Комбинированная терапия hcv инфекции |
Country Status (17)
Country | Link |
---|---|
US (1) | US20050112093A1 (ru) |
EP (1) | EP1670462A1 (ru) |
JP (1) | JP2007508326A (ru) |
KR (1) | KR20060120037A (ru) |
CN (1) | CN1882335A (ru) |
AR (1) | AR045870A1 (ru) |
AU (1) | AU2004281747A1 (ru) |
BR (1) | BRPI0415249A (ru) |
CA (1) | CA2541857A1 (ru) |
IL (1) | IL174864A0 (ru) |
MX (1) | MXPA06004077A (ru) |
NO (1) | NO20062104L (ru) |
PE (1) | PE20050477A1 (ru) |
RU (1) | RU2006115916A (ru) |
TW (1) | TW200528104A (ru) |
WO (1) | WO2005037274A1 (ru) |
ZA (1) | ZA200602912B (ru) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL194025B1 (pl) | 1996-10-18 | 2007-04-30 | Vertex Pharma | Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych |
SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
PE20050374A1 (es) | 2003-09-05 | 2005-05-30 | Vertex Pharma | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc |
US20120201883A1 (en) * | 2004-05-21 | 2012-08-09 | Accu-Break Technologies, Inc | Antiviral compositons |
TWI437990B (zh) * | 2004-10-29 | 2014-05-21 | Vertex Pharma | Vx-950之醫藥用途 |
CA2617679A1 (en) * | 2005-08-02 | 2007-02-08 | Steve Lyons | Inhibitors of serine proteases |
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
MX2008011868A (es) | 2006-03-16 | 2008-12-15 | Vertex Pharma | Inhibidores deuterados de la proteasa de la hepatitis c. |
US8575208B2 (en) * | 2007-02-27 | 2013-11-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
FR2928146B1 (fr) * | 2008-02-28 | 2010-02-19 | Saint Gobain Isover | Produit a base de fibres minerales et son procede d'obtention. |
WO2010033443A1 (en) * | 2008-09-17 | 2010-03-25 | Boehringer Ingelheim International Gmbh | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
JP2012517478A (ja) * | 2009-02-12 | 2012-08-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、hcv組合せ治療剤 |
CN102470162A (zh) * | 2009-06-30 | 2012-05-23 | 明治制果药业株式会社 | 用于治疗难治性c型慢性肝炎的药剂以及方法 |
EP2459211A1 (en) | 2009-07-31 | 2012-06-06 | Medtronic, Inc. | Continuous subcutaneous administration of interferon- to hepatitis c infected patients |
NZ598465A (en) | 2009-10-30 | 2013-10-25 | Boehringer Ingelheim Int | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
CH707029B1 (de) | 2011-10-21 | 2015-03-13 | Abbvie Inc | Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon. |
AU2013201532B2 (en) | 2011-10-21 | 2014-10-02 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
WO2017062840A1 (en) * | 2015-10-09 | 2017-04-13 | Trek Therapeutics, Pbc | Combination therapy for the treatment of hepatitis c virus |
US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
WO2017223178A1 (en) * | 2016-06-21 | 2017-12-28 | Trek Therapeutics, Pbc | Treating viral infections with impdh inhibitors |
WO2018169283A1 (ko) * | 2017-03-14 | 2018-09-20 | 국립암센터 | C형 간염 바이러스 질환 치료를 위한 리고세르팁의 신규 용도 |
CN109745315B (zh) * | 2019-03-08 | 2021-04-16 | 中国农业科学院兰州兽医研究所 | 一种Merimepodib在制备预防口蹄疫病毒感染的药物中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ298463B6 (cs) * | 1996-04-23 | 2007-10-10 | Vertex Pharmaceuticals Incorporated | Deriváty mocoviny pro použití jako inhibitory IMPDH enzymu a farmaceutické prostredky, které je obsahují |
MY129244A (en) * | 1998-05-15 | 2007-03-30 | Schering Corp | Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection. |
US6824769B2 (en) * | 2001-08-28 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Optimal compositions and methods thereof for treating HCV infections |
AU2003249659A1 (en) * | 2002-05-31 | 2003-12-19 | Schering Corporation | Combination therapy for rna virus infections involving ribavirin and impdh inhibitors |
-
2004
- 2004-10-08 AR ARP040103677A patent/AR045870A1/es not_active Application Discontinuation
- 2004-10-11 PE PE2004000979A patent/PE20050477A1/es not_active Application Discontinuation
- 2004-10-11 TW TW093130756A patent/TW200528104A/zh unknown
- 2004-10-12 JP JP2006534467A patent/JP2007508326A/ja active Pending
- 2004-10-12 ZA ZA200602912A patent/ZA200602912B/en unknown
- 2004-10-12 WO PCT/US2004/033739 patent/WO2005037274A1/en active Application Filing
- 2004-10-12 CN CNA2004800335847A patent/CN1882335A/zh active Pending
- 2004-10-12 KR KR1020067006996A patent/KR20060120037A/ko not_active Application Discontinuation
- 2004-10-12 BR BRPI0415249-2A patent/BRPI0415249A/pt not_active Application Discontinuation
- 2004-10-12 AU AU2004281747A patent/AU2004281747A1/en not_active Abandoned
- 2004-10-12 MX MXPA06004077A patent/MXPA06004077A/es not_active Application Discontinuation
- 2004-10-12 RU RU2006115916/15A patent/RU2006115916A/ru not_active Application Discontinuation
- 2004-10-12 CA CA002541857A patent/CA2541857A1/en not_active Abandoned
- 2004-10-12 US US10/964,243 patent/US20050112093A1/en not_active Abandoned
- 2004-10-12 EP EP04794964A patent/EP1670462A1/en not_active Withdrawn
-
2006
- 2006-04-09 IL IL174864A patent/IL174864A0/en unknown
- 2006-05-10 NO NO20062104A patent/NO20062104L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL174864A0 (en) | 2008-04-13 |
BRPI0415249A (pt) | 2006-12-12 |
EP1670462A1 (en) | 2006-06-21 |
NO20062104L (no) | 2006-05-10 |
JP2007508326A (ja) | 2007-04-05 |
ZA200602912B (en) | 2007-06-27 |
TW200528104A (en) | 2005-09-01 |
MXPA06004077A (es) | 2006-06-27 |
AR045870A1 (es) | 2005-11-16 |
CA2541857A1 (en) | 2005-04-28 |
US20050112093A1 (en) | 2005-05-26 |
AU2004281747A1 (en) | 2005-04-28 |
WO2005037274A1 (en) | 2005-04-28 |
CN1882335A (zh) | 2006-12-20 |
PE20050477A1 (es) | 2005-08-24 |
KR20060120037A (ko) | 2006-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2006115916A (ru) | Комбинированная терапия hcv инфекции | |
RU2007105354A (ru) | Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv) | |
JP2008518943A5 (ru) | ||
AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
RU2007119725A (ru) | Лекарственные формы | |
JP2002515453A5 (ru) | ||
BR0114636A (pt) | Terapia combinada para hcv de interferon-alfa peguilado/ribavirina | |
TW200716095A (en) | Method of treating interferon non-responders using HCV protease inhibitor | |
EA200701869A1 (ru) | Пептидомиметические ингибиторы протеазы | |
Manns et al. | Phase III results of Boceprevir in treatment naive patients with chronic hepatitis C genotype 1 | |
RU2011139180A (ru) | Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции | |
RU2010153688A (ru) | Режим дозирования телапревира | |
NZ502740A (en) | Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection | |
JP2005516041A5 (ru) | ||
PE20001386A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa | |
CN1835765A (zh) | 治疗病毒感染的方法 | |
JP2013542206A (ja) | C型肝炎ウイルス感染症の新規治療 | |
WO2009067225A4 (en) | Boceprevir derivatives for the treatment of hcv infections | |
WO2005016288A3 (en) | Methods and compositions for treatment of viral diseases | |
WO2005120540A3 (en) | Interferon alpha or beta for treatment of cardiomyopathy and endothelial dysfunction | |
RU2008109649A (ru) | ПЭГ-IFNα И РИБАВИРИН ДЛЯ ЛЕЧЕНИЯ ВИРУСА ГЕПАТИТА В | |
JP2001288110A5 (ru) | ||
JP2004529158A5 (ru) | ||
CN105749246A (zh) | 治疗丙肝病毒感染的阿拉泊韦 | |
DK1311279T3 (da) | Behandling af hepatitis C med thymosin, interferon og ribavirin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090326 |